Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26485417 | 0.88 | GPBAR1 (0.48) | GPBAR1ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL28608757 | 0.88 | GPBAR1 (0.47) | GPBAR1PTGS1ALDH1A1KDM4EKMT2A | |
| SCHEMBL22790165 | 0.86 | GPBAR1 (0.47) | GPBAR1PTGS1ALDH1A1KDM4EKMT2A | |
| SCHEMBL17358926 | 0.86 | GPBAR1 (0.50) | GPBAR1ALDH1A1KMT2AMEN1NR1H4 | |
| SCHEMBL25942183 | 0.85 | GPBAR1 (0.52) | GPBAR1ALDH1A1KMT2ANR1H4TSHR | |
| SCHEMBL17358925 | 0.85 | GPBAR1 (0.49) | GPBAR1ALDH1A1KMT2AMEN1NR1H4 | |
| SCHEMBL20031247 | 0.83 | NR1H4 (0.52) | GPBAR1KDM4ENR1H4 | |
| SCHEMBL28587444 | 0.83 | GPBAR1 (0.44) | GPBAR1PTGS1ALDH1A1KDM4EKMT2A | |
| SCHEMBL29556452 | 0.82 | NR1H4 (0.55) | NR1H4 | |
| SCHEMBL22570925 | 0.82 | EPAS1 (0.47) | GPBAR1PTGS1ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357244-A1 | FXR SMALL-MOLECULE AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230295141-A1 | FXR SMALL MOLECULE AGONIST, THE PREPARATION AND USE THEREOF | CASCADE PHARMACEUTICALS, INC. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20220213083-A1 | FXR SMALL MOLECULE AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF | VAN ANDEL RESEARCH INSTITUTE | 2022-07-07 | — | — | US | disclosed |
| WO-2022068815-A1 | FXR SMALL-MOLECULE AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2022-04-07 | — | — | WO | disclosed |
| WO-2020211872-A1 | FXR SMALL MOLECULE AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2020-10-22 | — | — | WO | disclosed |
| EP-2655370-B1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| EP-2655370-B1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20140039007-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | TULLY DAVID C (US) | 2014-02-06 | — | — | US | disclosed |
| US-20130331349-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2013-12-12 | — | — | US | disclosed |
| EP-2655370-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295141-A1 | FXR SMALL MOLECULE AGONIST, THE PREPARATION AND USE THEREOF | FXR1, NR1H4, FXR2 | GPBAR1 4/4885PTGS1 1197/4885ALDH1A1 2240/4885 |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | GPBAR1 6/4885PTGS1 1202/4885ALDH1A1 2611/4885 |
| US-20140039007-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | GPBAR1 2/4885PTGS1 1267/4885ALDH1A1 2875/4885 |
| US-20220213083-A1 | FXR SMALL MOLECULE AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF | FXR1, NR1H4, FXR2 | GPBAR1 4/4885PTGS1 840/4885ALDH1A1 2516/4885 |
| US-20230357244-A1 | FXR SMALL-MOLECULE AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | FXR1, NR1H4, FXR2 | GPBAR1 6/4885PTGS1 951/4885ALDH1A1 2161/4885 |
| US-20130331349-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | GPBAR1 5/4885PTGS1 1210/4885ALDH1A1 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.